Skip to main content

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Project description

Enhancing prediction of severe adverse effects early in the drug development pipeline

Around 9 of every 10 drug candidates fail to win approval. Drugs can often progress into phase III clinical trials - trials with patients - before some rare but potentially lethal side effects become apparent. This late-stage discovery has significant consequences for the time and cost of drug development. Safety pharmacology is a rapidly developing discipline that seeks to predict whether a drug is likely to be found unsafe if administered to human beings. INSPIRE plans to advance the field of safety pharmacology with a focus on cardiovascular events. Bringing together interrelated expertise including academics, pharmaceutical companies, hospitals, and regulators, the team is fostering innovation among early stage researchers to detect and minimise cardiovascular adverse events early in the pipeline.

Call for proposal

H2020-MSCA-ITN-2019
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

UNIVERSITEIT ANTWERPEN
Address
Prinsstraat 13
2000 Antwerpen
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 768 960

Participants (10)

UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 531 239,76
Address
Minderbroedersberg 4
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF NOTTINGHAM
United Kingdom
EU contribution
€ 606 345,12
Address
University Park
NG7 2RD Nottingham
Activity type
Higher or Secondary Education Establishments
INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AUTOMATIQUE
France
EU contribution
€ 274 802,04
Address
Domaine De Voluceau Rocquencourt
78153 Le Chesnay Cedex
Activity type
Research Organisations
NCARDIA BV

Participation ended

Netherlands
EU contribution
€ 0
Address
Gallileiweg 8
2333 BD Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UCB BIOPHARMA
Belgium
EU contribution
€ 256 320
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NOTOCORD SYSTEMS
France
EU contribution
€ 549 604,08
Address
Parc Les Grillons 60 Route De Sartr
78230 LE P Le Pecq
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TSE SYSTEMS GMBH
Germany
EU contribution
€ 252 788,40
Address
Siemenstrasse 21
61352 Bad Homburg Vor Der Hohe
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG
Germany
EU contribution
€ 252 788,40
Address
Binger Strasse 173
55218 Ingelheim
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
WEIZMANN INSTITUTE OF SCIENCE
Israel
EU contribution
€ 263 500,92
Address
Herzl Street 234
7610001 Rehovot
Activity type
Higher or Secondary Education Establishments
NCARDIA SERVICES BV
Netherlands
EU contribution
€ 265 619,88
Address
Gallileiweg 8
2333 BD Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)